立体定向放疗治疗TKI治疗中寡进展转移性肾细胞癌的前瞻性II期研究
结果显示1年局部控制率93%,中位PFS 9.3个月,1年更换系统治疗累积发生率47%,1年OS 92%,无3-5级SRT相关毒性。
要点
- SRT对TKI治疗中寡进展mRCC病灶1年局部控制率达93%
- SRT后中位PFS为9.3个月,更换系统治疗中位时间12.6个月
- 无3-5级SRT相关毒性,安全性良好
核心结论
- SRT对寡进展mRCC肿瘤局部控制率高,可将更换系统治疗的需求延迟中位超过1年。
主要发现
- 入组前中位TKI治疗时长18.6个月。
- 受照肿瘤1年局部控制率93%(95%CI 71-98%)。
- SRT后中位PFS 9.3个月(95%CI 7.5-15.7个月)。
- 1年更换系统治疗累积发生率47%(95%CI 32-68%),更换系统治疗中位时间12.6个月(95%CI 9.6-17.4个月)。
- 1年OS 92%(95%CI 82-100%),无3-5级SRT相关毒性。
临床怎么用
- 对TKI治疗中出现≤5个转移灶寡进展的mRCC患者,可考虑SRT并继续原TKI治疗以延迟更换系统治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is increasingly being considered in the setting of oligoprogression to delay the need to change systemic therapy. OBJECTIVE: To determine the local control (LC), progression-free survival (PFS), cumulative incidence of changing systemic therapy, and overall survival (OS) after SRT to oligoprogressive metastatic renal cell carcinoma (mRCC) lesions in patients who are on tyrosine kinase inhibitor (TKI) therapy. DESIGN, SETTING, AND PARTICIPANTS: A prospective multicenter study was performed to evaluate the use of SRT in oligoprogressive mRCC patients. Patients with mRCC who had previous stability or response after ≥3 mo of TKI therapy were eligible if they developed progression of five of fewer metastases. Thirty-seven patients with 57 oligoprogressive tumors were enrolled. INTERVENTION: Oligoprogressive tumors were treated with SRT, and the same TKI therapy was continued afterward. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Competing risk analyses and the Kaplan-Meir methodology were used to report the outcomes of interest. RESULTS AND LIMITATIONS: The median duration of TKI therapy prior to study entry was 18.6 mo; 1-yr LC of the irradiated tumors was 93% (95% confidence interval [CI] 71-98%). The median PFS after SRT was 9.3 mo (95% CI 7.5-15.7 mo). The cumulative incidence of changing systemic therapy was 47% (95% CI 32-68%) at 1 yr, with a median time to change in systemic therapy of 12.6 mo (95% CI 9.6-17.4 mo). One-year OS was 92% (95% CI 82-100%). There were no grade 3-5 SRT-related toxicities. CONCLUSIONS: LC of irradiated oligoprogressive mRCC tumors was high, and the need to change systemic therapy was delayed for a median of >1 yr. PATIENT SUMMARY: The use of stereotactic radiotherapy in metastatic kidney cancer patients, who develop growth of a few tumors while on oral targeted therapy, can significantly delay the need to change to the next line of drug therapy.
引用
- Cheung P, Patel S, North SA, et al. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. Eur Urol. 2021. PMID: 34399998. doi:10.1016/j.eururo.2021.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。